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Oesophageal adenocarcinoma is an aggressive malignancy with propensity for early lymphatic and haematogenous dissemination.
Since conventional TNM staging does not provide accurate prognostic information, novel molecular prognostic markers and potential
therapeutic targets are subject of intense research. The aim of the present study was to study the prognostic significance of Met, the
hepatic growth factor (HGF) receptor and a possible target for therapy in comparison to cyclooxygenase-2 (COX-2). Tumour
sections from 145 consecutive patients undergoing intentionally curative surgery for oesophageal adenocarcinoma were
immunohistochemically analysed for Met and COX-2 expression. Clinicopathological data were prospectively collected for all
patients. Patients with high Met expression had significantly reduced overall and disease-specific 5-year survival rates (Pp0.001 and
Pp0.001, respectively) and were more likely to develop distant metastases (P¼0.002) and local recurrences (P¼0.004) compared
to patients with low Met expression. High COX-2 expression tended to be correlated with poor long-term survival but this did not
reach statistical significance. Expression of Met was recognised as a significant and independent prognostic factor by stage-specific
analysis and multivariate analysis (relative risk¼2.3; 95% CI¼1.3–4.1). These findings support the importance of Met in oesophageal
adenocarcinoma and support the concept of Met tyrosine kinase inhibition as (neo-) adjuvant treatment.
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Oesophageal adenocarcinoma (OA) is a highly aggressive malig-
nancy with early lymphatic and haematogenous dissemination.
The incidence of OA is increasing rapidly in the Western World
(Enzinger and Mayer, 2003). Despite advances in diagnosis and
treatment of the disease, even after potentially curative surgery the
overall 5-year survival rate rarely exceeds 35% (Hulscher et al,
2002; Cunningham et al, 2006). Subgroup analysis in early-stage
tumours have shown good survival rates although even early-stage
tumours show early lymphatic dissemination.
For adenocarcinoma of the oesophagus the most important
conventional prognostic factors are summarised in the pTNM
stage of the oesophagus. Also other pathological aspects such as
extracapsular lymph node involvement and (relative) number of
positive nodes have prognostic impact. However, these conven-
tional prognostic factors have limited accuracy (Lagarde et al,
2006). Therefore, molecular prognostic markers, which can serve
as targets for therapy are subject of intense research. For OA only
few molecular prognostic factors have been identified and
molecular events responsible for the development of lymphatic
and haematogenous dissemination are still poorly understood
(Lagarde et al, 2006). Identification of growth factor receptors with
tyrosine kinase activity, highly expressed in advanced cancer, has
been shown to provide both prognostic information and potential
molecular targets for (neo-) adjuvant therapy (Krause and Van
Etten, 2005). A promising development in cancer therapy is the
combination of surgery with potent selective growth factor
receptor inhibitors as (neo-) adjuvant therapy resulting in
improved overall and disease-specific survival (Verweij et al,
2004; Krause and Van Etten, 2005; Gold and Dematteo, 2006;
Motzer et al, 2007; Smith et al, 2007). Therapeutic usage of small
molecules selectively inhibiting c-KIT, a growth factor receptor
present in gastrointestinal stromal cell tumours (GIST), has
resulted in remarkable responses and has enhanced prognosis
for patients with GIST to a great extent (Gold and Dematteo, 2006).
Other examples of targeted (neo-) adjuvant therapy are the
inhibition of vascular endothelial growth factor receptor (VEGFr)
in patients with advanced colorectal cancer, the inhibition of
HER2-Neu, an epidermal growth factor receptor in patients with
breast cancer and the inhibition of both VEGFr and platelet-
derived growth factor receptor (PDGFr) in patients with renal cell
carcinoma (Hurwitz et al, 2004; Verweij et al, 2004; Geyer et al,
2006; Motzer et al, 2007).
Growth factor receptors have been identified in OA and some
show higher expression in later stages of cancer development
(Lagarde et al, 2006; Vallbohmer et al, 2006). However, the
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sprognostic significance of growth factors expressed in OA has only
been investigated in relatively small patient cohorts and no
significance in multivariate analysis was demonstrated so far. The
only independent molecular prognostic factor demonstrated for
OA is cyclooxygenase-2 (COX-2) expression as published by our
group (Buskens et al, 2002; Lagarde et al, 2006). Recently, we have
reported a clinical study in which neo-adjuvant selective COX-2
inhibition downregulates Met expression in conjunction with
COX-2 expression in patients with OA (Tuynman et al, 2005). Met
is the hepatocyte growth factor (HGF) receptor and is identified in
OA (Tuynman et al, 2005; Anderson et al, 2006). Overexpression of
Met and/or its ligands has been shown to contribute to progression
and dissemination of several malignancies including lung, colo-
rectal, gastric, breast, prostate, thyroid, pancreas, and oesophageal
cancer (Hu et al, 2001; Saeki et al, 2002; Christensen et al, 2003;
Murai et al, 2004; Anderson et al, 2006). In experimental models,
activation of Met (endogenously by mutations in its tyrosine
kinase domain, or exogenously by HGF and prostaglandins
produced by COX-2) causes decreased apoptosis and enhanced
proliferation, angiogenesis, and invasion (Shinomiya et al, 2004;
Herrera et al, 2005; Boccaccio and Comoglio, 2006). Thus, COX-2
and Met seem functionally connected. In cancer development,
COX-2 is present in early stages of dysplasia, initiating cancer
growth and progression whereas Met is an important key regulator
of molecular processes in later stages of cancer development and
progression (Tuynman et al, 2004). Small molecules selectively
inhibiting Met have been shown to inhibit dissemination and
cancer growth both in vitro as in animal studies (Christensen et al,
2003; Kim et al, 2003; Hov et al, 2004; Herrera et al, 2005; Martens
et al, 2006; Watson et al, 2006). Consequently, inhibition of Met as
(neo-) adjuvant therapy for OA seems a promising strategy.
A relation between Met expression and stage of disease has been
described previously (Anderson et al, 2006). However, the
potential value of Met expression in OA as an independent
prognosticator calculated by multivariate analysis has not yet been
addressed in a large consecutive cohort. Therefore, the aim of the
present study was to characterize further the prognostic signifi-
cance of Met expression in a large consecutive cohort of patients
with OA.
PATIENTS AND METHODS
Patients
A consecutive series of 306 patients who underwent potentially
curative oesophagectomy at the Department of Surgery of the
Academic Medical Centre at the University of Amsterdam, The
Netherlands for adenocarcinoma of the mid/distal oesophagus
between January 1993 and December 2000 was selected. Pre-
operative workup included endoscopy with histological biopsy,
external ultrasonography of the abdomen and neck, CT scan of the
abdomen and chest, radiography of the chest, oesophageal
endosonography, and indirect laryngoscopy. Lymph node metas-
tases at the coeliac trunk were a contraindication for resection only
when considered non-resectable (i.e., larger than 2cm in diameter)
and confirmed by cytological puncture. Patients did not receive
additional (neo-) adjuvant chemotherapy and/or radiotherapy.
Clinicopathological data from all operated patients were perma-
nently prospectively collected. Follow-up was complete for all
patients and extended until July 2006, ensuring a minimal potential
follow-up of 5.5 years. Recurrence of disease was diagnosed on
clinical grounds. However, whenever a relapse was suspected,
radiologic, endoscopic, or histological confirmation was sought.
Recurrent disease was classified as locoregional (occurring in the
upper abdomen or mediastinum) or distant (including cervical
recurrences). All pathology reports were reviewed to identify those
patients in whom the adenocarcinoma had developed in a
histologically proven Barrett’s segment (defined by the presence
of goblet cells). Patients with an adenocarcinoma of the cardia or
gastro-oesophageal junction without a clear Barrett’s segment were
excluded (n¼161). This careful selection of patients has been
described in our previous report (Buskens et al, 2002). Archival
materials of the remaining 145 patients were re-evaluated to obtain
the sample with deepest invasion of each tumour.
Surgical tissue specimens
All 145 patients were treated with subtotal oesophagectomy and
resection of the lesser curvature of the stomach. Between April
1994 and February 2000, 96 patients (66%) were randomly
assigned to either transhiatal or transthoracic oesophagectomy as
part of a randomized trial comparing both techniques (Hulscher
et al, 2002). In the remaining 49 patients, a standard transhiatal
procedure was performed. In 95 patients (65.5%), resection was
performed by a transhiatal approach without thoracotomy.
Lymphadenectomy comprised en bloc removal of all lymphatic
tissue in the lower posterior mediastinum, along the cardia and the
lesser curvature of the stomach. Fifty patients (34.5%) underwent
oesophagectomy through a right-sided thoracotomy followed by a
laparotomy in combination with two-field lymph node dissection.
This procedure included an abdominal lymphadenectomy as
described plus the removal of lymph nodes along the common
hepatic artery, the splenic artery, and the coeliac trunk as well as
an extended lymph node dissection in the chest (i.e., including the
right paratracheal, infra-aortic arch, and subcarinal lymph nodes).
Immunohistochemistry
Of all patients 5-mm thick sections of paraffin and formaldehyde-
fixed tissue of the resection specimens were cut. For immuno-
histochemical staining, sections were incubated overnight at 371C
and subsequently deparaffinised in xylene, rehydrated, and treated
with 3% H2O2 in methanol for 10min to block endogenous
peroxidase activity. All specimens were subjected to heat-induced
antigen retrieval in 10mM sodium citrate buffer (pH 6.0) for
10min at 951C. To block aspecific binding the slides were
incubated with Tris-buffered saline (TBS) supplemented with 5%
goat serum. Sections were incubated with the primary antibodies
anti-Met c-Met (3D4; Zymed, San Francisco, CA, USA) (1:100),
and anti-human COX-2 (160112; Cayman Chemical Co., Ann
Arbor, MI, USA) (1:200) diluted in TBS with 1% bovine serum
albumin overnight at 41C. For the Met staining the sections were
incubated after washing steps with anti-mouse/rabbit-peroxidase
polymer for 30min at room temperature (Powervision; Immuno-
vision Inc., Daly City, CA, USA). Diaminobenzidine chromogen
(Sigma, St Louis, MO, USA) was used for visualisation. For the
COX-2 staining the sections were treated with biotinylated horse
anti-mouse immunoglobulin (1:200; Vector Laboratories Inc.,
Burlingame, CA, USA) and avidin–biotin peroxidase complex
(Vectastain ABComplex; Vector Laboratories). After these steps for
Met and COX-2 staining the sections were counterstained with
haematoxylin and embedded. Specificity of the antibodies was
confirmed by controls using irrelevant immunoglobulins instead
of primary antibodies. Colon cancer tissue was included as a
positive control.
Scoring
Met and COX-2 immunohistochemical staining were scored
semiquantitatively using a four-step scale as used and validated
in previous reports (Buskens et al, 2002; Tuynman et al, 2005). The
following scoring criteria of tumour cells were agreed upon before
the analysis: (0) no staining or equal to background; (1) weak
diffuse cytoplasmic staining (may contain stronger intensity in less
than 10% of cancer cells); (2) moderate granular cytoplasmic
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stained with strong intensity (Figure 1).
The analysis of all tissue sections was performed independently
by three different investigators (JBT, SML, and FJWTK) without
patient identification parameters to correct for observer accuracy.
The semiquantitative scoring by the investigators had a low
observer variation; 92% of the specimens were categorized
identically. In cases of disagreement (n¼6 for COX-2 expression
and N¼13 for Met expression) consensus was reached after re-
evaluation by the investigators using a multiheaded microscope.
Data regarding COX-2 staining intensity are equal as previously
described and used for the present analysis. Areas of diffuse
haemorrhage or necrosis were neglected.
Statistics
Statistical calculations were performed using SPSS version 14.0
(Statistical Package for the Social Sciences, Chicago, IL, USA). The
association between demographic and clinicopathological features
and protein expression was analysed using Student’s t-test
(continuous data) and w
2-test (categorical data). Overall and
disease-specific 5-year survival rates were estimated according to
the Kaplan–Meier method and compared between groups using
the log-rank test. Overall survival was calculated using deaths since
time of surgery irrespective of cause. For disease-specific survival
all non-disease-related deaths were excluded including in-hospital
death within 90 days of surgery, since we assumed that these
patients had died because of comorbidity and surgery-related
causes. The Cox proportional hazards regression model was used
to identify prognostic factors. To identify independent prognostic
factors multivariate Cox regression analysis was carried out.
Variables with multiple categories were recoded into dichotomous
variables by combining categories with a comparable prognosis
(differentiation grade, good vs moderate and poor (poor); tumour
T stage, stage 1 and 2 vs 3; Met expression, no or weak staining
(low) vs moderate to strong staining (high); COX-2 expression, no
or weak staining (low) vs moderate to strong staining (high).
RESULTS
A total of 145 consecutive patients with OA were included for
immunohistochemical analysis. Of these patients 120 were men
(83%) and 25 were women (17%) with a median age of 67 years
(range¼35–85) (Table 1). The majority of patients (N¼83, 57%)
had a T3 tumour and 80 patients (55%) had positive lymph nodes.
The overall 5-year survival in the included group was 35% and the
disease-specific 5-year survival was 48%. Two patients (1.4%) died
within 90 days due to post-operative complications (myocardial
and respiratory failure in one patient and cerebrovascular event in
another one patient).
High Met staining (as opposed to low Met staining) was
observed in 78 cases (54%). Of these 78 patients, 28 cases were
scored as strong Met expression and 50 as moderate Met
expression. In 67 patients (46%) Met expression was classified as
low; 56 patients had weak Met expression and 11 patients had no
or equal to background staining of Met. Met expression was
mainly localised in neoplastic cells (Figure 1A and B) but was also
weakly identified in non-neoplastic epithelial cells (both squamous
and columnar epithelium) and in stromal cells. Interobserver
Str
Str
Tu
Tu
Figure 1 Representive samples of immunohistochemical staining of Met
(A) and COX-2 (B) (Str¼stroma, T¼tumour).
Table 1 Correlation of clinicopathological findings and Met expression
Patient
characteristics
(n¼145) Overall
Low Met
expression
(N¼67)
High Met
expression
(N¼78) P-value
Median age (range) 67 (35–85) 67 (35–83) 68 (44–85) 0.493
Sex
Male (%) 120 (83%) 63 (94%) 57 (73%) 0.435
Tumour characteristics
T stage
a 0.017
T1 44 (30%) 29 (43%) 15 (19%)
T2 18 (12%) 8 (12%) 10 (13%)
T3 83 (57%) 30 (45%) 53 (68%)
N stage
b p0.001
N0 65 (45%) 38 (57%) 27 (35%)
N1 80 (55%) 29 (43%) 51 (65%)
M stage
c 0.086
M0 122 (84%) 58 (87%) 64 (82%)
M1a 23 (16%) 9 (13%) 14 (18%)
Differentiation grade 0.078
Good 11 (8%) 5 (7%) 6 (8%)
Moderate 56 (39%) 35 (52%) 21 (27%)
Poor 78 (54%) 27 (40%) 51 (65%)
Overall 5-year
survival
35% 57% 16% p0.001
Disease-specific 5-
year survival
48% 66% 33% p0.001
aT1, tumour limited to (sub)mucosa; T2, tumour infiltrates muscularis propia; T3,
tumour infiltrates adventitia layer; as determined in the pathological resection
specimens.
bN0, no tumour positive locoregional lymph nodes; N1, locoregional
lymph node metastasis.
cM0, no distant metastasis, M1a, metastasis in coeliac lymph
nodes.
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svariation was 8% for Met expression. All specimens that were
discrepant (n¼13) were re-evaluated and the consensus score was
used for further analysis. Results of COX-2 expression have been
described previously in this cohort of patients. Briefly, COX-2
expression was negative to weak in 21% (COX-2 low) and
moderate to strong in 79% (COX-2 high) of the carcinomas
(Buskens et al, 2002; Tuynman et al, 2005).
High Met expression was observed more often in patients with
higher T stage (P¼0.003), in patients with positive lymph nodes
(Pp0.001) and a poor differentiation grade (P¼0.003) (Table 1).
Met expression was not correlated with COX-2 expression
(P¼0.839).
During 5-year follow-up, 92 patients died: 17 patients died of
unrelated causes and 75 patients died of recurrent disease. Of these
patients, 23 had locoregional recurrences, 39 patients had
haematogenous recurrences and 13 patients had both locoregional
and haematogenous recurrences.
After a complete follow-up, overall 5-year survival was
significantly lower in patients with high Met expression as
compared to patients with low Met expression; 16 vs 57%
(Pp0.001). Furthermore, disease specific 5-year survival was
significantly lower in patients with high Met expression as
compared to patients with low Met expression; 33 vs 66%
(Pp0.001). Patients with high Met expression were more likely
to develop distant metastases (P¼0.002) as well as local
recurrences (P¼0.004). Patients with high COX-2 expression
tended to have a poor overall and disease-specific 5-year survival
as compared to patients with low COX-2 expression but in contrast
to previous reports this did not reach statistical significance
(Figure 2). Univariate analysis revealed that T stage, N stage, M1a
stage, differentiation grade, and Met expression were all significant
prognostic indicators for disease-specific 5-year survival (Table 2).
Multivariate analysis of these variables demonstrated that T3 stage
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
0.00 10.00 20.00 30.00 40.00 50.00 60.00
0.00 10.00 20.00 30.00 40.00 50.00 60.00 0.00 10.00 20.00 30.00 40.00 50.00 60.00
0.00 10.00 20.00 30.00 40.00 50.00 60.00
Overall survival in months
Overall survival in months
Met low
Met high
Met low
Met high
Disease-specific survival in months
Disease-specific survival in months
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
o
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
o
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
d
i
s
e
a
s
e
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
d
i
s
e
a
s
e
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l
COX-2 low
COX-2 high
COX-2 low
COX-2 high
P0.001 P0.001
P=0.180 P=0.238
Figure 2 Kaplan–Meier survival curves of 145 patients with adenocarcinoma of the oesophagus. Patients with high Met expression had a significantly
worse overall 5-year survival. (A)( Pp0.001) and disease-specific 5-year survival (Pp0.001) (B) as compared to patients with low Met expression. Overall
5-year survival and disease-specific 5-year survival tended to be worse in patients with high COX-2 expression (C and D, respectively) as compared to
patients with low COX-2 expression but this did not reach statistical significance (P¼0.180 and P¼0.238, respectively).
Table 2 Results of univariate analysis of clinical, pathological and
immunohistochemical parameters related to disease-specific 5-year survival
Odds ratio
(confidence interval) P-value
Patient sex (male vs female) 1.2 (0.7–2.3) 0.435
Patient ASA classification
(0 and 1 vs 2o r3 )
1.0 (0.5–2.0) 0.974
Patient age (70 and higher vs
lower than 70 years)
1.1 (0.5–2.2) 0.283
Tumour T stage (3 vs 1 and 2) 4.1 (2.4–7.2) 0.001
Tumour N stage (1 vs 0) 4.9 (2.8–8.6) 0.000
tumour M1a stage (1 vs 0) 3.7 (2.2–6.5) 0.035
Differentiation grade
(moderate and poor vs good)
2.2 (1.3–3.6) 0.015
Met expression (high vs low) 3.5 (2.0–5.9) 0.000
COX-2 expression (high vs low) 1.4 (0.8–2.6) 0.234
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3.5)), (P¼0.035)), lymph node involvement (RR¼2.8, (95%
CI¼1.5–5.3), (P¼0.001)) and high Met expression (RR¼2.3,
(95% CI¼1.3–4.1), (P¼0.004)) were independent prognostic
factors (Table 3).
Subgroup analysis in patients with Stages 1 and 2 OA revealed
that overall 5-year survival was significantly lower in patients with
high Met expression as compared to patients with low Met
expression (P¼0.007 and Pp0.001, respectively) (Figure 3).
Patients with stage 3 disease and high Met expression tended to
have poor overall 5-year survival as compared to patients with low
Met expression but no statistical significance was reached
(P¼0.064). In contrast to patients with stage 1 and 2, in patients
with stage 4 OA the Met expression level did not discriminate poor
vs better overall 5-year survival.
DISCUSSION
This study provides evidence that Met expression level (as detected
by immunohistochemical analysis) is an independent prognostic
factor in OA. Overall 5-year survival after potentially curative
resection is significantly worse in patients with tumours expressing
high Met levels compared to low Met levels.
In literature, lymphatic dissemination as identified on histo-
pathological examination is the single most important prognostic
factor in patients with oesophageal cancer (Lagarde et al, 2006).
Also in the present study, lymph node involvement is a strong
independent prognostic factor next to T stage and Met expression
level. Since Met expression was correlated stage of disease the
subgroup analysis revealed that especially in stage 1 and 2 OA Met
expression is a significant and valuable prognostic factor. In stage
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Figure 3 Stage specific Kaplan–Meier survival curves for high vs low Met expression. Patients with stage 1 (T1, N0, and M0) (A) and stage 2 (T2, 3, N0,
M0 or T1, N1, M0) (B) and high Met expression had a significantly worse overall 5-year survival as compared to patients with stage 1 or 2 with low Met
expression (P¼0.007 and Pp0.001, respectively). Patients with stage 3 (T3, N1, M0 or T4, N0, 1, M1a) (C) with high Met expression had a worse overall 5-
year survival as compared to patients with stage 3 with low Met expression however, this did not reach statistical significance (P¼0.061). High or low Met
expression in patients with stage 4 OA did not change the 5-year overall survival (P¼0.915) (D).
Table 3 Results of multivariate analysis of pathological and immunohis-
tochemical parameters related to disease-specific 5-year survival according
to the Cox regression model
Relative risk
(confidence interval) P-value
T stage (3 vs 1 and 2) 1.9 (1.0–3.5) 0.035
N stage (1 vs 0) 2.8 (1.5–5.3) p0.001
M1a stage (1a vs 0) 1.8 (0.9–3.4) 0.056
Tumour differentiation grade
(moderate and poor vs good)
1.6 (0.9–2.7) 0.077
Met expression (high vs low) 2.3 (1.3–4.1) 0.004
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s4 disease, Met expression level did not discriminate poor vs good
5-year overall survival indicating that in advanced stage OA other
factors determine survival. Since Met expression appears to be an
important independent prognosticator and especially, this might
offer an attractive opportunity for targeted therapy. Selective
inhibitors of Met have recently become available and successful
inhibition of tumour progression, stromal and endothelial adhe-
sion and dissemination has been reported both in vitro and in
animal studies. Targeted therapy of growth factor receptors has
been shown clinically effective in other cancer types such as
chronic myelogenous leukaemia, gastrointestinal stromal tumours,
HER-2/NEU overexpressing breast cancer, colorectal cancer and
non-small cell lung cancer (Verweij et al, 2004; Krause and Van
Etten, 2005; Gold and Dematteo, 2006; Motzer et al, 2007; Smith
et al, 2007).
A possible limitation of the present study is the semiquantitative
evaluation of immunohistochemistry. The rational to semiquanti-
tatively score Met and COX-2 immunohistochemically was to
compare results from earlier reports. These scoring methods have
been used and validated in our previous reports (Buskens et al,
2002; Tuynman et al, 2005). A significant advantage of immuno-
histochemistry is the cellular morphology, which helps to correct
for false-positive staining (blood vessels, stromal expression etc.).
Future studies using microarray gene expression technique can
help to validate results obtained in this patient cohort.
Surprisingly, COX-2 expression was not a significant prognostic
factor in this study. The same cohort of patients was employed for
the current analysis of Met expression as reported on earlier for
COX-2 expression (Buskens et al, 2002). In this study, a minimal
follow-up of 60 months was available whereas in the previous
study the median follow-up was only 27 months. Although survival
in patients with high COX-2 expression tended to be poorer than
that in patients with low COX-2 expression and this did not reach
statistical significance. Theoretically, the difference between COX-
2 expression and Met expression as prognostic indicators can
probably be explained by their function. The COX-2 enzyme is
enhanced in inflammation and has been shown to be involved in
early progression of oesophageal metaplasia and dysplasia into
(adeno-) carcinoma (Morris et al, 2001; Buskens et al, 2002;
Abdalla et al, 2004; Ling et al, 2007). Increased COX-2 expression
causes activation of several cancer-related genes including the HGF
receptor Met (Boon et al, 2004; Han et al, 2006). Vice versa COX-2
inhibition causes downregulation of cancer-related genes including
Met as it has been published previously by our group (Tuynman
et al, 2005). In comparison to COX-2, Met is involved later in the
process of cancer development and has been shown vital in cancer
progression (Boccaccio and Comoglio, 2006). The proto-oncogene
Met, also known as the scatter factor, has been shown particularly
important in morphogenic differentiation and organisation of
three-dimensional tubular structures as well as in cell growth and
loss of cellular adhesion causing migration (dissemination) of cells
(Boccaccio and Comoglio, 2006). Since OA is known for its
propensity to early lymphatic and haematogenous dissemination,
the strong prognostic significance of high Met expression for both
overall and disease-specific 5-year survival can explain this clinical
behaviour at least partly. These results suggest that employment of
new therapeutic agents targeting Met might be of value as (neo-)
adjuvant therapy in patients with OA, especially if Met expression
is high.
In conclusion, our data indicate that high Met expression is a
significant independent indicator of poor long-term survival in
patients after potentially curative resection of OA. Targeting this
receptor by a selective Met kinase inhibitor is an attractive (neo-)
adjuvant treatment option that should be tested especially in
patients with high tumoral Met expression.
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